Head to Head Comparison: Entera Bio (ENTX) & Momenta Pharmaceuticals (MNTA)

Entera Bio (NASDAQ:ENTX) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Entera Bio and Momenta Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio $500,000.00 92.15 N/A N/A N/A
Momenta Pharmaceuticals $75.59 million 18.06 -$176.06 million ($2.03) -6.82

Entera Bio has higher earnings, but lower revenue than Momenta Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings and price targets for Entera Bio and Momenta Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio 0 0 1 0 3.00
Momenta Pharmaceuticals 0 3 2 0 2.40

Entera Bio presently has a consensus price target of $12.00, suggesting a potential upside of 197.69%. Momenta Pharmaceuticals has a consensus price target of $23.54, suggesting a potential upside of 70.07%. Given Entera Bio’s stronger consensus rating and higher probable upside, research analysts plainly believe Entera Bio is more favorable than Momenta Pharmaceuticals.


This table compares Entera Bio and Momenta Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entera Bio N/A N/A N/A
Momenta Pharmaceuticals -231.49% -43.98% -33.82%

Insider & Institutional Ownership

8.9% of Entera Bio shares are held by institutional investors. Comparatively, 96.8% of Momenta Pharmaceuticals shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Entera Bio beats Momenta Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Entera Bio

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.